🗺 ABCT 103 · Course Map IP Strategy for Biotech Entrepreneurship
Six lectures, one page each. L1–L4 are the legal toolkit; L5 is what happens when it is contested; L6 is how a founder actually files. The 103 essay scope is L1–L6.
六講，每講一頁。L1–L4 是法律工具；L5 是工具被挑戰時的樣子；L6 是創辦人實際怎麼申請。103 申論範圍為 L1–L6。
103 · L1 IP Fundamentals
IP is both a legal instrument and an asset. Whether it becomes an enforceable patent turns on eligibility, written description and prior art.
IP 既是法律工具，也是資產。能否成為可執行專利，取決於可專利性、說明書支撐與是否落入 prior art。
103 · L2 Patenting in Biotechnology
The blockers for biotech patenting are genus support and natural-product eligibility. Getting a grant is not the same as being able to enforce it.
生物科技專利的攔路虎是 genus claim 的支撐與天然物的適格性；能申請不等於能執行。
103 · L3 Ethical & Controversial Aspects of Biotech Patenting
One set of cases, two readings: legally, eligibility; ethically, who may use genes and the research material built on them.
同一批判例，兩種讀法：法律上 Eligibility，倫理上則是誰能使用基因與生命的研究資料。
103 · L4 Commercial Aspects of Biotech IP
Patents and regulatory exclusivities are two walls built by two authorities; the five due-diligence questions decide whether a deal survives.
專利與法規獨佔是兩道牆，由兩個機構授予；盡職調查五問（ownership／validity／scope／FTO／coverage）決定交易成敗。
103 · L5 IP Litigation & Disputes in Biotech
A patent is a claim, not a right. In six recurring dispute types the structural difference decides it: China splits validity (CNIPA) from infringement (courts); the US unifies them.
專利是主張不是權利。六類糾紛中，論證的勝負往往取決於論證的結構：中國分軌（有效性給 CNIPA、侵權給法院），美國合軌。
103 · L6 Strategic IP Management for Biotech Start-ups
Strategic IP is the sum of four mistake-clusters: publishing before filing, filing without strategy, getting ownership wrong, and underinvesting until diligence exposes the gap.
策略性 IP 是四組錯誤的總和：先公開後申請、沒有申請策略、產權搞錯、以及投入不足而在盡調時暴露缺口。